The Pharma Data
DECEMBER 9, 2020
Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.
XTalks
APRIL 24, 2023
Melanie Blank, clinical team leader for General Medicine Branch 1 at the US Food and Drug Administration’s (FDA) Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), the agency is seeing one or two new applications coming in every week for new gene therapies for different diseases.
Pharmaceutical Technology
AUGUST 18, 2022
The latest approval is based on findings from the Phase III clinical trials, HGB-207 (Northstar-2) and HGB-212 (Northstar-3), and the long-term follow-up LTF-303 study. 0 genotypes. thalassemia in adult and paediatric patients. Findings showed that 89% of evaluable subjects attained transfusion independence (TI).
Expert insights. Personalized for you.
52 
Let's personalize your content